The Foundation is honoured to have been invited by The Texas Children’s Hospital to participate in their AE Day of Strength, for survivors and caregivers on Saturday, 27 July 2019, in Houston, Texas. Building on the success of last year’s event, titled AE Day of Hope, the theme this year will be Strength.This special event will bring together patients and their families affected by autoimmune encephalitis to connect with other affected families, to exchange stories of shared hardship and ways of coping, as well as learning about the latest updates in the field of neuro-immunology. No one should have to face the hardships of autoimmune encephalitis alone and what better way than to dedicate a day and shine a stark bright light on a group of diseases that few had heard of, until their loved-one was stricken. The global AE family is growing and strengthened thanks to the contribution, leadership and solidarity with patients and their families of The Texas Children’s Hospital. The Foundation’s founding president, Ms. Nesrin Shaheen is looking forward to making the keynote presentation and to meeting patients and their families. If you are in the Houston area or can travel, we would love to see you there.
|
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
|
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
|
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune inflammatory brain disease that can develop a variety of neuropsychiatric presentations. However, the underlying nature of its inflammatory neuronal injury remains unclear.
|
Accumulating data on patients with autoimmune encephalitis have shed light on specificities concerning clinical presentation and outcomes, which are dependent on the antigen targeted by the autoantibodies found in the patients’ cerebrospinal fluid or sera. Such specificities include seizure‐related clinical manifestations as well as the responsiveness to antiepileptic drugs. Although increased enthusiasm accompanies the discovery of novel antibodies and their associated clinical syndromes, several issues remain unsettled. First, it appears that therapy needs to be personalized in the view of the severity of each antibody‐mediated syndrome, patient‐related characteristics, and timing of treatment. Second, the lack of randomized controlled trials is a major drawback in the formulation of an appropriate immunotherapeutic strategy. In this review, we discuss the novel developments and challenges for the diagnosis and treatment of epilepsy in patients with well‐characterized autoimmune encephalitis, and delineate the principles for a rational approach toward precision medicine in this emerging field.
|
We describe an adolescent female presenting with first-episode isolated psychosis
due to anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and ovarian teratoma.
Rapid improvement in symptoms occurred after immunotherapy and tumor removal.
|
|
Neuropsychopharmacology Reviews…
|
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
|
Among autoimmune encephalitis, patients with anti-N-methyl D- aspartate receptor (NMDAR) encephalitis typically present epileptic seizures, memory deficits and psychiatric symptoms. However, the signal mechanisms leading to the functional disorders of autoantibodies are largely unclear.
|
Using advanced technology, scientists have discovered an autoimmune disease that appears to affect men with testicular cancer.
|
Scientist at UC Santa Barbara helps develop animal model for one type of encephalitis, a damaging brain disease…
|
|
